(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide,

DMSO:42.67(Max Conc. mg/mL);112.17(Max Conc. mM)DMSO:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.31(Max Conc. mM)DMF:30.0(Max Conc. mg/mL);78.87(Max Conc. mM)Ethanol:76.0(Max Conc. mg/mL);199.8(Max Conc. mM)

Upadacitinib;ABT-494;ABT-494(Upadacitinib) free base;Upadacitinib (ABT-494);ABT-494 (Upadacitinib);Upadacitinib (Rinvoq);ABT-494; ABT494; ABT 494;CS-2730

InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1

Introduction Upadacitinib is a JAK1 inhibitor that has shown good efficacy in clinical trials for the treatment of a variety of autoimmune and inflammatory diseases. Efficacy Upadatinib has shown good efficacy in clinical trials for the treatment of a variety of autoimmune and inflammatory diseases. Upatinib is a small molecule oral targeted drug developed by AbbVie, a leading international biopharmaceutical company. It was approved last year for the treatment of atopic dermatitis (AD) and rheumatoid arthritis (AD) in adults and adolescents aged 12 years and above. RA) and psoriatic arthritis (PsA), have become the selective JAK1 inhibitors with the most indications in my country. In vitro studies In biochemical assays, atorvastatinib was 74 times more selective for JAK-1 than JAK-2 (which is involved in erythropoiesis) and 58 times more selective for JAK-1 than JAK-3 (which is involved in immune monitoring). Selective enhancement of JAK-1 over JAK-2 and JAK-3 by U Chemicalbook AADACITIB may provide improved risk-risk profiles across the spectrum of RA. In vivo studies Upadacitinib, the second JAK inhibitor developed by AbbVie, is described as a second-generation inhibitor. The multi-dose Phase I study was completed in 2013. In a Phase I trial, using an immediate-release formulation, upadacitinib was found to be safe and well tolerated up to multiple doses of 24 mg twice daily. Upadacitinib exposure was dose proportional across multiple doses evaluated. Purpose Scientific research reagents are widely used in molecular biology, pharmacology and other scientific research areas. It is strictly prohibited to be used on the human body. Upadacitinib (ABT-494) is a highly efficient and selective JAK1 inhibitor used in the treatment of some autoimmune diseases and research in related fields.

Upadacitinib is a JAK1 inhibitor that has shown good efficacy in clinical trials for the treatment of a variety of autoimmune and inflammatory diseases.